NeuroPace (NASDAQ:NPCE – Get Free Report) had its price objective boosted by equities research analysts at Cantor Fitzgerald from $19.00 to $20.00 in a report issued on Wednesday,Benzinga reports. The ...

Revenue: US$79.9m (up 22% from FY 2023). Net loss: US$27.1m (loss narrowed by 18% from FY 2023). US$0.93 loss per share ...

Q4 2024 Earnings Call Transcript March 4, 2025 NeuroPace, Inc. beats earnings expectations. Reported EPS is $-0.18, ...

Please go ahead. Thank you for joining us for Neuropace's fourth quarter and full year 2024 Financial and operating results conference call. On today's call, we will hear from Joel Becker ...

Greetings and welcome to NeuroPace Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation.

March 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the ...

NeuroPace Inc. (NPCE) reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an adjusted earnings per share (EPS) of -$0.18 versus the forecasted -$0.25. The company also ...

MOUNTAIN VIEW, Calif. (AP) — MOUNTAIN VIEW, Calif. (AP) — NeuroPace Inc. (NPCE) on Tuesday reported a loss of $5.3 million in its fourth quarter. The Mountain View, California-based company ...

March 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for ...

MOUNTAIN VIEW, Calif. (AP) — MOUNTAIN VIEW, Calif. (AP) — NeuroPace Inc. (NPCE) on Tuesday reported a loss of $5.3 million in its fourth quarter. The Mountain View, California-based company said it ...